WO1999058096A3 - Analogues de l'acide 2-phthalimidinoglutarique - Google Patents

Analogues de l'acide 2-phthalimidinoglutarique Download PDF

Info

Publication number
WO1999058096A3
WO1999058096A3 PCT/US1999/010287 US9910287W WO9958096A3 WO 1999058096 A3 WO1999058096 A3 WO 1999058096A3 US 9910287 W US9910287 W US 9910287W WO 9958096 A3 WO9958096 A3 WO 9958096A3
Authority
WO
WIPO (PCT)
Prior art keywords
analogs
phthalimidinoglutaric
phthalimidinoglutaric acid
methyl
angiogenesis
Prior art date
Application number
PCT/US1999/010287
Other languages
English (en)
Other versions
WO1999058096A9 (fr
WO1999058096A2 (fr
Inventor
Jamshed H Shah
Glenn M Swartz
Adonia E Papathanassiu
William E Fogler
John W Madsen
Shawn J Green
Original Assignee
Entremed Inc
Jamshed H Shah
Glenn M Swartz
Adonia E Papathanassiu
William E Fogler
John W Madsen
Shawn J Green
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Entremed Inc, Jamshed H Shah, Glenn M Swartz, Adonia E Papathanassiu, William E Fogler, John W Madsen, Shawn J Green filed Critical Entremed Inc
Priority to EP99925585A priority Critical patent/EP1091726A2/fr
Priority to JP2000547948A priority patent/JP2002514578A/ja
Priority to CA002331461A priority patent/CA2331461C/fr
Priority to AU41837/99A priority patent/AU749356B2/en
Publication of WO1999058096A2 publication Critical patent/WO1999058096A2/fr
Publication of WO1999058096A3 publication Critical patent/WO1999058096A3/fr
Publication of WO1999058096A9 publication Critical patent/WO1999058096A9/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/44—Iso-indoles; Hydrogenated iso-indoles
    • C07D209/46—Iso-indoles; Hydrogenated iso-indoles with an oxygen atom in position 1
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Rheumatology (AREA)
  • Communicable Diseases (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurology (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Indole Compounds (AREA)

Abstract

La présente invention concerne des analogues nouveaux et utiles de l'acide 2-phthalimidinoglutarique. Les analogues comprennent l'acide DL-2- méthyl-2- phthalimidinoglutarique et des analogues hydroxylés de 2-phthalimidinoglutarique. L'invention englobe également des procédés de fabrication de ces analogues. Elle concerne également les deux enantiomères de l'acide DL-2- méthyl-2- phthalimidinoglutarique, l'acide (R)-(+)-2- méthyl-2- phthalimidinoglutarique et l'acide (S)-(-)-2-méthyl-2-phthalimidinoglutarique ainsi que les procédés permettant de séparer ces énantiomères individuels du racémique vrai. De plus, cette invention, s'intéresse à des méthodes permettant d'inhiber l'angiogenèse et de traiter des affections en rapport avec l'angiogenèse, dont le cancer et la dégénérescence maculaire, par administration d'un ou de plusieurs de ces composés.
PCT/US1999/010287 1998-05-11 1999-05-11 Analogues de l'acide 2-phthalimidinoglutarique WO1999058096A2 (fr)

Priority Applications (4)

Application Number Priority Date Filing Date Title
EP99925585A EP1091726A2 (fr) 1998-05-11 1999-05-11 Analogues de l'acide 2-phthalimidinoglutarique
JP2000547948A JP2002514578A (ja) 1998-05-11 1999-05-11 ２−フタルイミジノグルタル酸の類似体および血管新生の阻害剤としてのそれらの使用
CA002331461A CA2331461C (fr) 1998-05-11 1999-05-11 Analogues de l'acide 2-phthalimidinoglutarique
AU41837/99A AU749356B2 (en) 1998-05-11 1999-05-11 Analogs of 2-phthalimidinoglutaric acid and their use as inhibitors of angiogenesis

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US8503798P 1998-05-11 1998-05-11
US60/085,037 1998-05-11
US9738498P 1998-08-21 1998-08-21
US60/097,384 1998-08-21
US10803798P 1998-11-12 1998-11-12
US60/108,037 1998-11-12

Publications (3)

Publication Number Publication Date
WO1999058096A2 WO1999058096A2 (fr) 1999-11-18
WO1999058096A3 true WO1999058096A3 (fr) 2000-05-18
WO1999058096A9 WO1999058096A9 (fr) 2000-07-13

Family

ID=27374997

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1999/010287 WO1999058096A2 (fr) 1998-05-11 1999-05-11 Analogues de l'acide 2-phthalimidinoglutarique

Country Status (6)

Country Link
EP (1) EP1091726A2 (fr)
JP (1) JP2002514578A (fr)
KR (1) KR100699968B1 (fr)
AU (1) AU749356B2 (fr)
CA (1) CA2331461C (fr)
WO (1) WO1999058096A2 (fr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7182953B2 (en) * 1999-12-15 2007-02-27 Celgene Corporation Methods and compositions for the prevention and treatment of atherosclerosis restenosis and related disorders
JP4361273B2 (ja) 2001-02-27 2009-11-11 アメリカ合衆国 潜在的な血管形成阻害剤としてのサリドマイド類似体
CA2504263A1 (fr) * 2002-10-31 2004-05-21 Celgene Corporation Methodes d'utilisation et compositions contenant des substances medicamenteuses d'inhibition selective des cytokines pour traiter et controler la degenerescence
US7776907B2 (en) 2002-10-31 2010-08-17 Celgene Corporation Methods for the treatment and management of macular degeneration using cyclopropyl-N-{2-[(1S)-1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl]-3-oxoisoindoline-4-yl}carboxamide
CN1867331B (zh) 2003-09-17 2010-05-26 美国政府健康及人类服务部 作为TNF-α调节剂的沙利度胺类似物
US8952895B2 (en) 2011-06-03 2015-02-10 Apple Inc. Motion-based device operations
US8927725B2 (en) 2011-12-02 2015-01-06 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Thio compounds
CN102603610B (zh) * 2012-02-21 2014-07-09 四川大学 1,3-二氢-1-氧-2h-异吲哚类化合物、其制备方法和用途
CN104045594B (zh) * 2012-02-21 2016-08-17 四川大学 一类1,3-二氢-1-氧-2h-异吲哚类化合物及其用途
US9617212B2 (en) 2013-12-17 2017-04-11 Controlled Chemicals, Inc. Isoindolin-1-ones as macrophage migration inhibitory factor (MIF) inhibitors
CN109467550B (zh) * 2017-12-31 2022-02-18 苏州亚科科技股份有限公司 一种邻苯二甲酰胺基-l-谷氨酸酐的合成方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994020085A1 (fr) * 1993-03-01 1994-09-15 The Children's Medical Center Corporation Procedes et compositions pour inhiber l'angiogenese
EP0688771A1 (fr) * 1994-06-24 1995-12-27 Grünenthal GmbH Utilisation de composés lactames comme agents pharmaceutiques

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994020085A1 (fr) * 1993-03-01 1994-09-15 The Children's Medical Center Corporation Procedes et compositions pour inhiber l'angiogenese
EP0688771A1 (fr) * 1994-06-24 1995-12-27 Grünenthal GmbH Utilisation de composés lactames comme agents pharmaceutiques

Also Published As

Publication number Publication date
KR20010052332A (ko) 2001-06-25
AU4183799A (en) 1999-11-29
WO1999058096A9 (fr) 2000-07-13
AU749356B2 (en) 2002-06-27
CA2331461C (fr) 2008-10-07
EP1091726A2 (fr) 2001-04-18
KR100699968B1 (ko) 2007-03-28
JP2002514578A (ja) 2002-05-21
WO1999058096A2 (fr) 1999-11-18
CA2331461A1 (fr) 1999-11-18

Similar Documents

Publication Publication Date Title
WO2002064083A3 (fr) Synthese de 3-amino-thalidomide et de ses enantiomeres
CA2322204A1 (fr) 5-aminoindeno(1,2-c)-pyrazol-4-ones agents anticancereux et antiproliferatifs
CA2449729A1 (fr) Promedicaments d'analogues de gaba, compositions et utilisations desdits promedicaments
WO2002076976A3 (fr) Inhibiteurs de rho-kinase
WO2002076977A3 (fr) Inhibiteurs de rho-kinase
WO2005002626A8 (fr) Composes de phosphonate therapeutiques
WO2005018557A3 (fr) Pyridinones substitues
WO2005051304A3 (fr) Inhibiteurs de la proteine kinase akt
CA2337991A1 (fr) Benzocycloheptenes, procede de production de ces composes preparations pharmaceutiques contenant ces composes et utilisation de ces composes pour la preparation de medicaments
WO1999058096A3 (fr) Analogues de l'acide 2-phthalimidinoglutarique
WO2003045330A3 (fr) Materiaux et procedes d'obtention de compositions de micelles
WO2002040484A3 (fr) Nouveaux derives imidazole, procede de production correspondant et utilisation de ces derives
ES8704482A1 (es) Procedimiento para la preparacion de silibinina extenta de isosilibina
GB0322510D0 (en) Novel compounds
WO2003007883A3 (fr) Acylsemicarbazides inhibiteurs de kinase dependant de la cycline utiles en tant qu'agents anticancereux et antiproliferatifs
WO2006019685A3 (fr) Composes et leur preparation pour le traitement de la maladie d'alzheimer par inhibition de la production de peptides beta-amyloides
WO2001000617A3 (fr) Nouveaux derives de piperazinyl-alkyl-thiopyrimidine compositions pharmaceutiques les contenant et procede de preparation de la substance active
EP1958939A3 (fr) Composes pyrazole-amines utilises dans le traitement des troubles neurodegeneratifs
WO2004073375A3 (fr) Derives de podophyllotoxine utiles comme agents antitumoraux
MXPA02001204A (es) Compuestos calciliticos.
WO2001080845A3 (fr) Substances et méthodes de traitement de la dépression
WO2002016327A8 (fr) Benzimidazoles et analogues et utilisation de ces derniers comme inhibiteurs neutrophiles
WO2002046163A3 (fr) Derives de quinoleine et leur utilisation
WO2005020911A3 (fr) Composes de benzo[1, 3]dioxole, leurs compositions pharmaceutiques, et methodes de production et d'utilisation desdits composes
WO2004062596A3 (fr) Composes d'ether lipidique antineoplasiques possedant un squelette comportant 4 atomes de carbone

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

AK Designated states

Kind code of ref document: C2

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: C2

Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

COP Corrected version of pamphlet

Free format text: PAGES 1/14-14/14, DRAWINGS, REPLACED BY NEW PAGES 1/14-14/14; DUE TO LATE TRANSMITTAL BY THE RECEIVING OFFICE

ENP Entry into the national phase

Ref document number: 2331461

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 1020007012550

Country of ref document: KR

ENP Entry into the national phase

Ref country code: JP

Ref document number: 2000 547948

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 41837/99

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 1999925585

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 1999925585

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1020007012550

Country of ref document: KR

WWG Wipo information: grant in national office

Ref document number: 41837/99

Country of ref document: AU

WWR Wipo information: refused in national office

Ref document number: 1020007012550

Country of ref document: KR